Therapeutic strategies using c-erbB-2 promoter-controlled drug activation.
Sikora
K
K
ICRF Oncology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
Harris
J
J
Hurst
H
H
Lemoine
N
N
D001943:Breast Neoplasms / Q000628:therapy*; D002277:Carcinoma / Q000628:therapy; D043525:Cytosine Deaminase; D066246:ErbB Receptors / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D066298:In Vitro Techniques; D009700:Nucleoside Deaminases / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011355:Prodrugs / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; D012190:Retroviridae / Q000235:genetics; D014407:Tumor Cells, Cultured
D043525:Cytosine Deaminase; D066246:ErbB Receptors; D009700:Nucleoside Deaminases; D011355:Prodrugs; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins